Clear Creek Bio has dosed the first patient in phase 1 clinical study of brequinar in hospitalised patients with Covid-19.
The company has secured clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application of brequinar to treat Covid-19.
Brequinar is an orally available, potent, and selective small-molecule DHODH inhibitor, which can inhibit host cell de novo pyrimidine biosynthesis that is crucial for DNA and RNA synthesis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,